Takeda Ventures
Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world.
Business Model:
Revenue: $30.4B
Employees: 10,001-999,999
Rankings
Industries / Tags:
Detailed Takeda Ventures Information
Geographic Data
Address: 1-1, Nihonbashi-Honcho 2-chome
City: Tokyo
State: tōkyō prefecture
Zip: 103-8668
Country: JP
Financial Info
Stage:
Raised Last:
$0
Raised Total:$8B
Social
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&a;D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda&s;s considerable R&a;D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 10/2017 | Portal Instruments | Venture Round | 6M |
| 6/2007 | Serenex | Series D | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 12/2014 | Naurex | Series C | 0 |
| 10/2005 | Serenex | Series C | 30M |
| 3/2021 | Presage Biosciences | Convertible Note | 6M |
| 11/2022 | hC Bioscience | Series A | 0 |
| 1/2020 | Emendo Biotherapeutics | Series B | 61M |
| 5/2020 | Amwell | Series C | 0 |
| 11/2019 | Protekt Therapeutics | Venture Round | 4.1M |
| 12/2013 | VHSquared | Series A | - |
| 5/2017 | OrphoMed | Series A | 39M |
| 10/2018 | Bsense Bio Therapeutics | Seed Round | 405k |
| 1/2020 | EvolveImmune Therapeutics | Venture Round | 17.5M |
| 7/2012 | Juventas Therapeutics | Series B | 0 |
| 2/2019 | Hookipa Pharma | Series D | 37.4M |
| 2/2022 | Koneksa Health | Series C | 0 |
| 5/2021 | BridGene Biosciences | Series A | 0 |
| 9/2018 | Ramino Bio | Seed Round | - |
| 10/2020 | Be Biopharma | Series A | 52M |
| 9/2020 | Palleon Pharmaceuticals | Series B | 100M |
| 10/2019 | Arcellx | Series B | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 4/2021 | Adaptate Biotherapeutics | Series A | 18.2M |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 2/2023 | Cerevance | Series B | 0 |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 10/2018 | VelosBio | Series A | 58M |
| 10/2021 | Egle Therapeutics | Series A | 0 |
| 6/2021 | Transine Therapeutics | Seed Round | 0 |
| 10/2007 | CellCentric | Venture Round | 4.3M |
| 6/2016 | Ultragenyx Pharmaceutical | Post-IPO Equity | 65M |
| 8/2016 | Bioniz Therapeutics | Series A | 0 |
| 8/2018 | Ambys Medicines | Series A | 60M |
| 11/2012 | ArmaGen Technologies | Series A | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 5/2018 | Cortexyme | Series B | 76M |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 6/2011 | Redwood Bioscience | Venture Round | - |
| 5/2011 | Naurex | Series A | 18M |
| 6/2013 | Heptares Therapeutics | Series B | 0 |
| 10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
| 4/2005 | Receptor Biologix | Series A | 33.6M |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 7/2018 | Presage Biosciences | Series D | 6M |
| 5/2023 | OncoResponse | Venture Round | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 5/2023 | Larkspur Biosciences | Series A | 0 |
| 10/2009 | Envoy Therapeutics | Series A | 8M |
| 8/2015 | Presage Biosciences | Venture Round | - |
| 4/2017 | Cortexyme | Debt Financing | 8M |
| 7/2018 | ARTham Therapeutics | Series A | - |
| 1/2018 | SEEDSUPPLY | Seed Round | - |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 2/2022 | hC Bioscience | Series A | 0 |
| 1/2021 | Aspen RxHealth | Series B | 23M |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 7/2004 | Serenex | Venture Round | 8M |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 12/2021 | Integra Therapeutics | Seed Round | 0 |
| 12/2015 | Prosetta Biosciences | Series D | 31M |
| 7/2020 | VelosBio | Series B | 137M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 2/2018 | Wave Life Sciences | Post-IPO Equity | 60M |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 5/2017 | GammaDelta Therapeutics | Venture Round | 100M |
| 3/2011 | CellCentric | Series B | - |
| 9/2015 | Encycle Therapeutics | Venture Round | 0 |
| 2/2019 | BIOMx | Series B | 0 |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 8/2022 | Zelluna Immunotherapy | Venture Round | - |
| 11/2022 | Enzyre | Series A | 0 |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 11/2018 | Axcelead | Seed Round | - |
| 4/2021 | Code Biotherapeutics | Seed Round | 0 |
| 4/2022 | Be Biopharma | Series B | 0 |
| 1/2006 | Symphogen | Series D | 0 |
| 1/2016 | Cortexyme | Series A | 15M |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 5/2017 | BIOMx | Series A | 24M |
| 4/2020 | Cerevance | Series B | 65M |
| 2/2010 | Domainex | Venture Round | - |
| 1/2020 | Transine Therapeutics | Seed Round | - |
| 9/2014 | BioMotiv | Venture Round | 25M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 5/2023 | Larkspur Biosciences | Series A | 0 |
| 5/2023 | OncoResponse | Venture Round | 0 |
| 2/2023 | Cerevance | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 11/2022 | hC Bioscience | Series A | 0 |
| 11/2022 | Enzyre | Series A | 0 |
| 8/2022 | Zelluna Immunotherapy | Venture Round | - |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 4/2022 | Be Biopharma | Series B | 0 |
| 2/2022 | hC Bioscience | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
